Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01711658 · ClinicalTrials.gov registry record · Phase 2
TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.
A Phase 2 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
NCT01711658 is a Phase 2 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 142 participants.
The verdict
NCT01711658, a Phase 2 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
Study Summary
PURPOSE: This trial is studying if and how well lapatinib adds to the effectiveness of radiation therapy plus cisplatin in patients who have head and neck cancer that is not related to the human papillomavirus (HPV).
Interventions
- DRUG Cisplatin
- DRUG placebo
- RADIATION IMRT
- DRUG Lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2013-03-15 |
| Est. Completion | 2022-09-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01711658
The ClinicalTrials.gov registry entry for NCT01711658 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 142 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cisplatin is the first listed.
NCT01711658 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01711658 about?
NCT01711658 is a clinical study titled "TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer.". PURPOSE: This trial is studying if and how well lapatinib adds to the effectiveness of radiation therapy plus cisplatin in patients who have head and neck cancer that is not related to the human papillomavirus (HPV).
What is the current status of trial NCT01711658?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2013-03-15. Estimated completion is 2022-09-21.
What interventions are being tested in trial NCT01711658?
The interventions under investigation include: Cisplatin (DRUG), placebo (DRUG), IMRT (RADIATION), Lapatinib (DRUG).
Who is sponsoring clinical trial NCT01711658?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.